Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $475.00 at Evercore ISI

Intuitive Surgical (NASDAQ:ISRG) had its price target upped by stock analysts at Evercore ISI from $410.00 to $475.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “in-line” rating on the medical equipment provider’s stock. Evercore ISI’s price target indicates a potential downside of 2.15% from the stock’s current price.

Several other equities research analysts have also commented on ISRG. Truist Financial boosted their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Barclays boosted their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Robert W. Baird boosted their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Finally, Piper Sandler boosted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $449.70.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG traded down $5.84 during trading on Tuesday, hitting $485.43. 438,321 shares of the company were exchanged, compared to its average volume of 1,486,136. The company has a market cap of $172.18 billion, a price-to-earnings ratio of 87.53, a PEG ratio of 5.39 and a beta of 1.39. Intuitive Surgical has a 1 year low of $254.85 and a 1 year high of $496.18. The firm’s fifty day moving average price is $473.63 and its 200 day moving average price is $429.56.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 EPS. On average, research analysts forecast that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Activity

In other news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock valued at $25,528,753 in the last 90 days. 0.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical during the 2nd quarter valued at approximately $26,000. Creekmur Asset Management LLC increased its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares during the period. LGT Financial Advisors LLC increased its position in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares during the period. Delos Wealth Advisors LLC increased its holdings in shares of Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Finally, LRI Investments LLC acquired a new position in shares of Intuitive Surgical during the first quarter valued at $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.